Montreal / Philadelphia / Portland / Basel / Helsinki / Boston / Sydney / Leuven / Melbourne / London / /
Company
Transgenomic Inc. / Bernstein / Eastern Cooperative Oncology Group / Bone Sarcoma Group / Novartis Pharma AG / 8Novartis Pharma AG / Southwest Oncology Group / Mesa RA / International Working Group / /
Continent
Europe / North America / /
Country
Switzerland / Canada / Australia / United Kingdom / Finland / / /
Event
FDA Phase / /
Facility
Royal Prince Alfred Hospital / Dana-Farber Cancer Institute / MacCallum Cancer Institute / University Hospital Basel / 9University Hospital / Portland VA Medical Center / Science University Cancer Institute / Helsinki University Central Hospital / Women’s Hospital / 5Hammersmith Hospital / Institute of Pathology / / /
IndustryTerm
magnetic resonance imaging / Cancer Therapy / treatment of advanced KIT-mutated melanoma / gene product / /
Imperial College School of Medicine / 5Hammersmith Hospital / 11Peter MacCallum Cancer Institute / 1Oregon Health & Science University Cancer Institute / 3Harvard Medical School / American Association for Cancer Research / 4Harvard Medical School / Helsinki University Central Hospital / Institute of Pathology / Women’s Hospital / ND ND / Dana-Farber Cancer Institute / 9University Hospital / Princess Margaret Hospital / Portland VA Medical Center / Department of Hematology and Medical Oncology / Royal Prince Alfred Hospital / AACR Publications Department / /
Person
Van Etten / Van Beurden / Michael C. Heinrich / Van Oosterom / George D. Demetri / Heikki Joensuu / / /